Showing results (31-40 of 36) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Journal of Medicinal Chemistry|September 16, 2005
Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agentsSamuel Chackalamannil, Yan Xia, William J Greenlee, et al.Bioorganic & Medicinal Chemistry Letters|January 24, 2007
Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidinesBernard R Neustadt, Jinsong Hao, Neil Lindo, et al.Naunyn-Schmiedeberg'S Archives of Pharmacology|February 28, 2013
Effects of telmisartan or amlodipine monotherapy versus telmisartan/amlodipine combination therapy on vascular dysfunction and oxidative stress in diabetic ratsHanke Mollnau, Matthias Oelze, Elena Zinßius, et al.Bioorganic & Medicinal Chemistry Letters|December 29, 2005
Discovery and synthesis of a novel series of quinoline-based thrombin receptor (PAR-1) antagonistsMartin C Clasby, Samuel Chackalamannil, Michael Czarniecki, et al.Journal of Medicinal Chemistry|January 5, 2007
Metabolism-based identification of a potent thrombin receptor antagonistMartin C Clasby, Samuel Chackalamannil, Michael Czarniecki, et al.The Journal of Pharmacology and Experimental Therapeutics|April 1, 2009
Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depressionRobert A Hodgson, Rosalia Bertorelli, Geoffrey B Varty, et al.Pageof 4